Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. engages in research, development, production, marketing and sales of  pharmaceutical products in People’s Republic of China (“PRC”) through its operating subsidiary, Laiyang Jiangbo Pharmaceuticals Co., Ltd. (“Laiyang Jiangbo”). Jiangbo purchases patents for drugs or develops sophisticated drugs through collaboration with leading research institutions. The Company is well positioned to benefit from rapidly growing pharmaceutical market in China by its well known brand, experienced management, skilled workforce and extensive distribution network.The company is located in Northeast China in an Economic Development Zone, Laiyang City , Shandong Province. 

     

Jiangbo has 470 full time sales representatives and 620 part time representatives located in all major commerce areas across China. The company has numerous GMP (Chinese State Drug Administration or the SDA) approved manufacturing facilities and production lines, to produce various forms of Traditional Chinese Medicines and Western Medicines. The Company has a production capacity of 6 billion tablets, 70 million boxes of granules and 50 million boxes of capsules. 12 million bottles of Syrup and 8 million bottles of electuary.The acquisition of Hongrui in January 2009 increased Jiangbo' product portfolio from 6 to 28 products. The Company's best selling products include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Baobaole Chewable Tablets, Radix Isatidis Dispersible Tablets. In addition, the Company has recently received the SFDA final approval for production of Felodipine Sustained Release Tablets.